William Freeman, MD
Ophthalmology · San Diego, CANPI 1518983352
Payments from drug & device makers
Across 199 payments — averaging $5008.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$330K
- Janssen Research & Development, LLC$297K
- Apellis Pharmaceuticals, Inc.$190K
- AstraZeneca$53K
- Amgen$47K
- Astellas Pharma Global Development$30K
- plus $49K from 9 others
Across 3 payments — averaging $3927.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$12K
What the payments were for
- Consulting fees$22,88087%
- Speaking & faculty fees$9253%
- Travel & lodging$1,0074%
- Food & beverage$1,6186%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 78 | $329,965 |
| Janssen Research & Development, LLC | 42 | $297,173 |
| Apellis Pharmaceuticals, Inc. | 21 | $189,579 |
| AstraZeneca | 4 | $53,480 |
| Amgen(2 entities) | 8 | $47,388 |
| Astellas Pharma Global Development | 9 | $30,034 |
| Regeneron | 10 | $24,921 |
| AbbVie(2 entities) | 10 | $13,959 |
| Alcon | 10 | $8,364 |
| F. Hoffmann-la Roche AG | 1 | $925 |
| Lensar, Inc. | 1 | $309 |
| Lumibird Medical Inc. | 2 | $232 |
| Harrow Eye, LLC | 1 | $212 |
| Novartis | 1 | $60 |
| Ocular Therapeutix, Inc. | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$8,184
- SUSVIMO$1,680
- Lucentis$925
- Non-Covered Product$368
- LENSAR LASER SYSTEM$309
- VEVYE$212
- TANGO OPTIMO$174
- Avastin$119
How this compares
$996,643 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 14 | $1,060 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $720 |
| Ketorolac Tromethamine | 24 | $372 |
| Brimonidine Tartrate | 16 | $127 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Diego
- Eric NudlemanSan Diego$752K
- Robert WeinrebSan Diego$660K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.